COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

Protocol No
MERCK-MK-7902-009
Principal Investigator
Aditya Shreenivas
Phase
II
Summary
This project is being done to test the safety of the trial drugs, lenvatinib and pembrolizumab (pembro), for the treatment of head and neck squamous cell carcinoma (HNSCC) that has returned or spread after previous treatment.
Description
Lenvatinib with or without Pembrolizumab And SOC For R/M HNSCC After Platinum And Immunotherapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category